Bionumerik pharmaceuticals acquired
WebDec 17, 2024 · BioNumerik Pharmaceuticals Inc. - Company Profiles - BCIQ. Company Profiles. Target Profiles. Product Profiles. Latest Articles Commentaries Deals Distillery … WebAug 1, 2006 · BioNumerik has two drug candidates in late-stage clinical development: Tavocept(TM) and Karenitecin (BNP1350). Contacts: Takeda Pharmaceutical Company Limited Corporate Communications Dept. (PR/IR) Seizo Masuda [email protected] Tel: +81-6-6204-2060 BioNumerik Pharmaceuticals, Inc. …
Bionumerik pharmaceuticals acquired
Did you know?
WebFunding. BioNumerik Pharmaceuticals has raised a total of $63.3M in funding over 3 rounds. Their latest funding was raised on Nov 8, 2012 from a Venture - Series Unknown … WebBioNumerik Pharmaceuticals, Inc. Lantern Pharma, Inc. By: /s/ David R. Margrave : By: /s/ Arunkumar Asaithambi: Name: Name: Arunkumar Asaithambi, Ph.D. Title: Title: Chief …
WebBioNumerik Pharmaceuticals focuses on the discovery, development, and commercialization of novel drugs for the treatment of cancer and cancer-supportive care. It provides drugs by merging medicine, quantum and statistical mechanics, pharmaceutical development, and supercomputing. The company was founded in 1992 and is based in … WebBioNumerik Pharmaceuticals General Information Description Operator of an oncology pharmaceutical company focused on discovering and developing novel pharmaceutical …
WebBionumerik Pharmaceuticals designs and develops small molecule drugs for the treatment of cancer and prevention of side effects associated with existing cancer therapies. WebBioNumerik Pharmaceuticals, Inc. Street Address 1 Street Address 2; 8122 DATAPOINT DRIVE: SUITE 1250: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; SAN ANTONIO: TEXAS: 78229: 210-614-1701: 3. Related Persons. Last Name First Name Middle Name; Hausheer: Frederick: H. Street Address 1 Street Address 2; 8122 …
Web51 to 200 Employees. Type: Company - Private. Industry: Biotech & Pharmaceuticals. Revenue: $5 to $25 million (USD) Competitors: Unknown. BioNumerik …
Web51 to 200 Employees. Type: Company - Private. Industry: Biotech & Pharmaceuticals. Revenue: $5 to $25 million (USD) Competitors: Unknown. BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential cancer drugs, the company has brought two candidates into late ... react i18n githubWebFeb 7, 2008 · SAN ANTONIO, Feb. 7 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. today announced treatment of the first patient in a global Phase III clinical trial of BioNumerik's anticancer drug candidate known as Karenitecin(R) in advanced ovarian cancer patients. BioNumerik is developing Karenitecin (also known as BNP1350) as an … react i18next change language based countryWebAug 27, 2009 · BioNumerik Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT00966914 Other Study ID Numbers: DMS32212R : First Posted: August 27, 2009 Key Record Dates: Last Update Posted: July 13, 2024 Last Verified: July 2024 Additional relevant MeSH terms: Layout table for MeSH terms ... react icon color changeWebNov 8, 2012 · BioNumerik Pharmaceuticals raised $10,190,500 / Series Unknown. Discover more funding rounds . Funding Round ... how to start looking up family historyWebAug 9, 2024 · LP-300 was in-licensed from BioNumerik Pharma in May 2016 and acquired from them in January 2024. Following acquisition of the license, Lantern planned a … how to start lovenoxWebJun 14, 2012 · SAN ANTONIO, June 14, 2012 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced the appointment of Mr. Steve Carchedi to BioNumerik's Board of Directors. react i tagWebJul 17, 2008 · SAN ANTONIO, July 17 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced that patients with adenocarcinoma (the most frequently occurring form of lung cancer) participating in a Phase II clinical trial of Tavocept(TM) showed a survival increase of approximately 198 days (6.5 months). The trial … react iamge